Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.

Journal of endocrinological investigation - 1 Nov 2024

Losa M, Mazza E, Pedone E, Nocera G, Liscia N, Reni M, Mortini P

Abstract excerpt

BACKGROUND: Papillary craniopharyngiomas harbor the BRAF V600E mutation, which paves the way for using BRAF inhibitor molecules to treat tumors refractory to standard therapies. Single case reports confirmed the efficacy of targeted therapy. However, most reports were limited by the short follow-up. We describe the long-term course of a patient treated with dual-agent BRAF and MEK inhibitors and review the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Craniopharyngioma
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Pituitary Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 38696125
DOI: 10.1007/s40618-024-02382-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.PMID 38696125Read ↗

Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.Semantic proximity Read ↗

Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.Semantic proximity Read ↗

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.Semantic proximity Read ↗

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutationsSemantic proximity Read ↗

[Molecularly Targeted Therapy for Craniopharyngioma].Semantic proximity Read ↗

BRAF plus MEK inhibition effective in papillary craniopharyngioma.Semantic proximity Read ↗

Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.Semantic proximity Read ↗

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.Semantic proximity Read ↗

Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.Semantic proximity Read ↗

Targeted therapies in the medical management of craniopharyngioma.Semantic proximity Read ↗

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngiomaSemantic proximity Read ↗

Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.